Yung Samuel, Han Duhyun, Lee Jason K
Can Respir J. 2015 Nov-Dec;22(6):315-6. doi: 10.1155/2015/265734. Epub 2015 Sep 24.
Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been used as an effective treatment for severe asthma associated with atopy over the past decade. Sarcoidosis is an idiopathic granulomatous disorder in which first-line treatment is usually glucocorticoids. To the authors' knowledge, the present report describes the first case of an association between omalizumab therapy and revelation of cutaneous sarcoidosis with the withdrawal of systemic glucocorticoids. A 56-year-old woman with severe allergic asthma dependent on oral prednisone initiated omalizumab treatment. As her symptoms of asthma improved over the course of a year, her prednisone was gradually tapered. After being off glucocorticoids, she developed skin nodules that had biopsy characteristics of sarcoidosis. The present case illustrates the need to monitor closely for potential unmasking of glucocorticoid-responsive conditions when transitioning from systemic glucocorticoids to omalizumab therapy.
奥马珠单抗是一种单克隆抗免疫球蛋白E抗体，在过去十年中一直被用作治疗与特应性相关的重度哮喘的有效药物。结节病是一种特发性肉芽肿性疾病，一线治疗通常是糖皮质激素。据作者所知，本报告描述了首例奥马珠单抗治疗与停用全身糖皮质激素后皮肤结节病显露之间存在关联的病例。一名56岁依赖口服泼尼松的重度过敏性哮喘女性开始接受奥马珠单抗治疗。随着她的哮喘症状在一年中有所改善，泼尼松逐渐减量。停用糖皮质激素后，她出现了具有结节病活检特征的皮肤结节。本病例表明，在从全身糖皮质激素过渡到奥马珠单抗治疗时，需要密切监测是否可能出现糖皮质激素反应性疾病的显露情况。
